Printify
Women's Champion Sweatshirt (Purple Ribbon)
Women's Champion Sweatshirt (Purple Ribbon)
Couldn't load pickup availability
Wrap yourself in warmth and purpose with the Champion of Hope Crewneck, a sweatshirt designed for those who proudly support pancreatic cancer awareness and research. This eco-friendly Champion sweatshirt combines the brand's renowned quality with Double Dry® technology, ensuring all-day warmth and comfort. With “Supporter” printed boldly on the back, it’s a statement of solidarity, courage, and dedication to the cause.
Crafted from a durable blend of 50% cotton and 50% polyester, including 5% recycled polyester from plastic bottles, this crewneck is as sustainable as it is stylish. The iconic Champion "C" logo on the left sleeve adds a touch of heritage and authenticity to the design, making it perfect for casual outings or layered up for cooler days.
40% of revenue from each Champion of Hope Crewneck goes to Sky Foundation, a 501(c)3 non-profit that spreads pancreatic cancer awareness and funds research, allowing you to wear your support with pride, knowing that every purchase contributes to finding a cure.
- 50% cotton, 50% polyester blend for warmth and durability
- Medium-heavy fabric (9 oz/yd² or 310 g/m²)
- Regular fit with sewn-in label
- Eco-friendly material includes 5% recycled polyester from plastic bottles
- Champion "C" logo on the left sleeve for an iconic finish
Share



Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...